WALTHAM, Mass.–(BUSINESS WIRE)–ZebiAI, Inc., a biotech company focused on improving human health by powering machine learning (ML) to source novel targets and discover new therapeutics, today announced the appointment of Brian Goldman, Ph.D., as SVP and Chief Computation Officer.
Dr. Goldman brings almost thirty years of experience in algorithms and software for molecular modeling, cheminformatics, medicinal chemistry, and image analysis. He spent the past 20 years at Vertex, where he led the methods group in the Modeling and Informatics department and focused on applying ML methods to impact drug discovery programs.
Dr. Goldman has deep chemistry roots, having earned his Ph.D. in Chemistry from the University of California at Santa Cruz where he studied differential geometry as applied to molecular surfaces and molecular similarity calculations. Prior to joining Vertex, he worked at CombiChem, a computational drug discovery firm.
“We are thrilled to welcome Brian to ZebiAI,” said Rick Wagner, Ph.D., founder and CEO of ZebiAI. “We have established a scientific team with deep expertise in chemistry and applying ML to drug discovery alongside our partner Google Accelerated Science, and Brian is a key addition to our leadership brain trust. He brings extensive computational drug discovery expertise and shares our vision for rapidly accelerating the discovery and development of new medicines with ML.”
“I am very excited to join the ZebiAI team,” said Dr. Goldman. “ZebiAI and Google Accelerated Science have made incredible strides in the advancement of ML-driven drug discovery. As a chemist and computational scientist, I believe ZebiAI offers a unique combination of differentiated data, well-honed ML methods, and the ability to rapidly uncover novel biology. I look forward to driving drug discovery programs in critical disease areas forward rapidly through the application of ML.”
About ZebiAI Therapeutics
ZebiAI Therapeutics is a privately held biotechnology company based in Waltham, Massachusetts, focused on improving human health by powering machine learning (ML) to source novel targets and discover new therapeutics. The company’s core technology encompasses applying advanced ML algorithms to vast amounts of the highest quality protein-small molecule data to discover novel compounds from unlimited chemical space and then further utilizing ML to advance compounds to clinical candidates. As one of its core strategic programs, ZebiAI, together with its partner Google Accelerated Science, is applying its ML-driven discovery platform to efficiently deliver new chemical probes to the research community for thousands of human proteins to unlock novel biological targets responsible for human disease.